Elsevier

Vaccine

Volume 21, Issues 11–12, 7 March 2003, Pages 1125-1136
Vaccine

Immunisation with modified HPV16 E7 genes against mouse oncogenic TC-1 cell sublines with downregulated expression of MHC class I molecules

https://doi.org/10.1016/S0264-410X(02)00519-4Get rights and content

Abstract

Human papillomavirus type 16 (HPV16)-transformed mouse TC-1 cells are extensively used in the evaluation of efficacy of experimental vaccines against tumours induced by HPVs. As these cells strongly express MHC class I molecules and downregulation of MHC class I surface expression is one of the important mechanisms that enable tumour escape from the host immune system, we undertook to derive TC-1 clones with reduced expression of MHC class I antigens. TC-1 cells were inoculated into mice preimmunised with an E7 gene-based DNA vaccine and from tumours developing in a portion of the animals, cell clones with downregulated MHC class I surface expression were isolated. Treatment with IFN-γ resulted in an upregulation of MHC class I molecules in these cells, but after IFN-γ removal, their expression gradually dropped again. When the expression of some components of the antigen-processing machinery (APM; LMP-2, TAP-1, and TAP-2) was tested, a reduced TAP-1 production was detected in cell lines with downregulated MHC class I expression. An enhanced immunoresistance of TC-1-derived clones with reduced MHC class I expression was observed in animals immunised with plasmids carrying modified E7 genes. Apart from the previously described fusion gene Sig/E7/LAMP-1, a new construct, Sig/E7GGG/LAMP-1, with a mutated Rb-binding site, was also used for immunisation. No significant change of immunogenicity was recorded for Sig/E7GGG/LAMP-1. Cell lines with downregulated MHC class I expression derived from TC-1 cells may represent a useful model for testing therapeutic anti-HPV vaccines in settings more relevant to clinical requirements.

Introduction

Infection with human papillomavirus (HPV) can result in the development of a benign or a malignant tumour, the most serious HPV-associated disease being cervical carcinoma (CC) [1]. World-wide, CC is the second most common malignancy in women. However, most HPV infections are asymptomatic and transient and more than half of the untreated mild precancerous lesions regress spontaneously [2]. Immune surveillance seems to be responsible for HPV elimination, seeing that people with acquired or congenital immunodeficiency are at increased risk of CC. Accordingly, vaccination against the ‘high risk’ HPV types might suppress the development of HPV-induced diseases. Both therapeutic and prophylactic anti-HPV vaccines are being developed at the present time [3], [4], [5], [6]. While prophylactic vaccines should prevent HPV infection by inducing neutralising antibodies, therapeutic vaccines would be required to elicit cell-mediated immune responses capable of killing transformed cells. The only viral products consistently present in all transformed cells are oncoproteins E6 and E7 [7], which are necessary for both oncogenic transformation and maintenance of the transformed state. Therefore, they represent the targets of choice in the development of HPV-specific vaccines directed against CC.

Several different anti-HPV vaccines are being tested in animal models and in clinical trials [3], [6]. Because of many advantages, DNA immunisation represents one of the most promising approaches [8]. In order to increase the immunogenicity of the E7 oncogene, it has been modified in various ways and enhanced anti-tumour responses induced by E7-based DNA vaccines have been obtained. (i) The E7 gene has been fused with the sorting signals of lysosome-associated membrane protein 1 (LAMP-1; fusion gene Sig/E7/LAMP-1) [9], [10], [11], [12], the heat-shock protein 70 (Hsp70) of M. tuberculosis [13], the translocation domain of Pseudomonas aeruginosa exotoxin A [14], the extracellular domain of the Flt3-ligand [15], or the VP22 protein of herpes-simplex virus type 1 [16], [17]; (ii) E7 has been mutated in two zinc-binding motifs [18] or in the binding site for pRb tumour-suppressor protein (Rb-binding site) [19].

During tumour development, transformed cells are under the pressure of the host’s immune system. This leads to the selection of cells with adaptations that provide them with a survival advantage [20]. One of the mechanisms that enable cell escape from the immune system is reduction of the surface expression of the major histocompatibility complex (MHC) class I molecules [21]. This reduction has been recorded in up to 70–90% of CC patients [22], [23]. In patients at an early stage of tumour development, downregulated MHC class I production has been found associated with a worsened prognosis [24]. Moreover, metastatic cells have been shown to have lower MHC class I expression in comparison with cells from primary tumours [25].

A downregulation of MHC class I expression may be effected by several mechanisms, which give rise to distinct phenotypes [26], [27]. Defects in the antigen-processing machinery (APM) are often responsible for a low level of MHC class I surface expression [28]. Decreased levels of APM components have been demonstrated in many human [29], [30], [31], [32], [33], [34], [35] and mouse tumour cells [36]. Moreover, an association between the oncogenic transformation of cells and the downregulation of APM and MHC class I expression has been established [37], [38], [39].

At present, mouse oncogenic TC-1 cells are most often used in testing the efficacy of experimental therapeutic vaccines against the most common ‘high risk’ HPV type, i.e. HPV16, which is present in about 50% of CCs [40]. This cell line has been prepared by transformation of primary lung cells with HPV16 E6 and E7 oncogenes and activated H-ras [10]. The cells express a high level of MHC class I molecules. However, any population of cells forming a tumour is heterogeneous in MHC class I expression [41]. Therefore, an anti-tumour vaccine should induce immunity against tumour cells with a variable MHC class I production.

In this study, we derived clones of TC-1 cells with a decreased MHC class I expression. Some of the properties of these clones were tested and the mechanisms which might be involved in the MHC class I downregulation were partially analysed. The clones were used to verify the efficacy of DNA vaccination with the Sig/E7/LAMP-1 gene, which had previously been shown to induce a strong immune response against TC-1 cells [11], [12]. Mutations in the Rb-binding site that had been shown to improve the immunogenicity of E7 [19] were introduced into Sig/E7/LAMP-1 and the resulting gene, Sig/E7GGG/LAMP-1, was compared with Sig/E7/LAMP-1.

Section snippets

Plasmids

The construction of plasmids pBSC, pBSC/E7, pBSC/E7GGG, pBSC/L1E7, and pBSC/E7LAMP was described previously [19]. In brief, pBSC is an “empty” plasmid carrying the immediate early cytomegalovirus promoter. Downstream this promoter, the following genes: wild-type HPV16 E7 (pBSC/E7), mutated E7GGG [19] (pBSC/E7GGG), fusion L1ΔCE71-60 [42] (pBSC/L1E7), and fusion Sig/E7/LAMP-1 [9] (pBSC/E7LAMP) were cloned into the XhoI site. The immunogenicity of all these constructs had been tested in previous

TC-1 clones with downregulated MHC class I expression

To obtain TC-1 cells with downregulated expression of MHC class I molecules, we prepared cell lines from tumours formed in an immunisation/challenge experiment reported previously [19]. In that experiment, mice were immunised twice with plasmid pBSC/E7, pBSC/E7GGG, pBSC/L1E7, or pBSC/E7LAMP and challenged with 104 TC-1 cells. Tumours developed in all non-immunised control mice, but only in a portion of the immunised animals. Some of them were excised on reaching a diameter of 1.0–1.5 cm and 10

Discussion

From HPV16-transformed mouse TC-1 cells, which expresses a high level of MHC class I molecules, several cell clones with downregulated surface expression of these molecules were derived. The clones were obtained from a tumour that developed in a mouse immunised with an E7 gene-containing plasmid, i.e. under conditions favouring the selection of tumour cells with enhanced immunoresistance. The reduction of MHC class I expression was reversible, seeing that IFN-γ treatment led to its

Acknowledgements

We wish to thank Mrs. V. Navrátilová for technical assistance. This work was supported by Grant No. NC/5900-3 obtained from the Internal Grant Agency, Ministry of Health of the Czech Republic, by Research Project No. CEZ MZ 0023736001 of Institute of Hematology and Blood Transfusion, Prague, by Grant Nos. 312/99/0542 and 301/02/0852/A from the Grant Agency of the Czech Republic, and by the Czech Terry Fox Foundation.

References (70)

  • D.M. Pardoll et al.

    The role of CD4+ T cell responses in antitumor immunity

    Curr. Opin. Immunol.

    (1998)
  • D. Street et al.

    Interferon-gamma enhances susceptibility of cervical cancer cells to lysis by tumor-specific cytotoxic T cells

    Gynecol. Oncol.

    (1997)
  • H. zur Hausen

    Papillomavirus infections—a major cause of human cancers

    Biochim. Biophys. Acta

    (1996)
  • K. Nasiell et al.

    Behavior of mild cervical dysplasia during long-term follow-up

    Obstet. Gynecol.

    (1986)
  • T.L. Cornelison

    Human papillomavirus genotype 16 vaccines for cervical cancer prophylaxis and treatment

    Curr. Opin. Oncol.

    (2000)
  • M. Ling et al.

    Preventive and therapeutic vaccines for human papillomavirus-associated cervical cancers

    J. Biomed. Sci.

    (2000)
  • H. zur Hausen

    Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis

    J. Natl. Cancer Inst.

    (2000)
  • S. Gurunathan et al.

    DNA vaccines: immunology, application, and optimization

    Annu. Rev. Immunol.

    (2000)
  • T.C. Wu et al.

    Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens

    Proc. Natl. Acad. Sci. U.S.A.

    (1995)
  • K.Y. Lin et al.

    Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen

    Cancer Res.

    (1996)
  • C.H. Chen et al.

    Gene gun-mediated DNA vaccination induces antitumor immunity against human papillomavirus type 16 E7-expressing murine tumor metastases in the liver and lungs

    Gene Ther.

    (1999)
  • H. Ji et al.

    Targeting human papillomavirus type 16 E7 to the endosomal/lysosomal compartment enhances the antitumor immunity of DNA vaccines against murine human papillomavirus type 16 E7-expressing tumors

    Hum. Gene Ther.

    (1999)
  • C.H. Chen et al.

    Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene

    Cancer Res.

    (2000)
  • C.F. Hung et al.

    Cancer immunotherapy using a DNA vaccine encoding the translocation domain of a bacterial toxin linked to a tumor antigen

    Cancer Res.

    (2001)
  • C.F. Hung et al.

    Enhancement of DNA vaccine potency by linkage of antigen gene to a gene encoding the extracellular domain of Fms-like tyrosine kinase 3-ligand

    Cancer Res.

    (2001)
  • C.F. Hung et al.

    Improving vaccine potency through intercellular spreading and enhanced MHC class I presentation of antigen

    J. Immunol.

    (2001)
  • W.F. Cheng et al.

    Enhancement of sindbis virus self-replicating RNA vaccine potency by linkage of herpes simplex virus type 1 VP22 protein to antigen

    J. Virol.

    (2001)
  • W. Shi et al.

    Human papillomavirus type 16 E7 DNA vaccine: mutation in the open reading frame of E7 enhances specific cytotoxic T-lymphocyte induction and antitumor activity

    J. Virol.

    (1999)
  • S.J. Pettit et al.

    Immune selection in neoplasia: towards a microevolutionary model of cancer development

    Br. J. Cancer

    (2000)
  • G. Pawelec et al.

    Escape mechanisms in tumor immunity: a year 2000 update

    Crit. Rev. Oncol.

    (2000)
  • P.J. Keating et al.

    Frequency of down-regulation of individual HLA-A and -B alleles in cervical carcinomas in relation to TAP-1 expression

    Br. J. Cancer

    (1995)
  • L.A. Koopman et al.

    Multiple genetic alterations cause frequent and heterogeneous human histocompatibility leukocyte antigen class I loss in cervical cancer

    J. Exp. Med.

    (2000)
  • M.E. Connor et al.

    Evaluation of multiple biological parameters in cervical carcinoma: high macrophage infiltration in HPV-associated tumours

    Int. J. Gynecol. Cancer

    (1993)
  • F.V. Cromme et al.

    Differences in MHC and TAP-1 expression in cervical cancer lymph node metastases as compared with the primary tumours

    Br. J. Cancer

    (1994)
  • N.P. Restifo et al.

    Identification of human cancers deficient in antigen processing

    J. Exp. Med.

    (1993)
  • Cited by (71)

    • A prime/boost strategy by DNA/fowlpox recombinants expressing a mutant E7 protein for the immunotherapy of HPV-associated cancers

      2012, Virus Research
      Citation Excerpt :

      The resulting E7GGG protein can also increase its immunogenicity and therapeutic efficacy (Edmonds and Vousden, 1989; Heck et al., 1992; Smahel et al., 2001) by prevention of native-E7-mediated inhibition of dendritic cell differentiation (Frazer et al., 1999). This mutagenized E7GGG, alone or fused to carriers, was previously used in mice as a recombinant DNA vaccine (Massa et al., 2008, 2011; Smahel et al., 2001, 2003) or as plant-produced protein (Massa et al., 2007; Venuti et al., 2009), and it induced a complete immune response, which protected the mice against E7-expressing tumors. The aim of this study was to generate plasmid DNA and fowlpox recombinants expressing the modified HPV-16 E7GGG gene and test their therapeutic efficacy in prime-boost protocols.

    • Human papillomavirus 16E6 suppresses major histocompatibility complex class I by upregulating lymphotoxin expression in human cervical cancer cells

      2011, Biochemical and Biophysical Research Communications
      Citation Excerpt :

      LT and TNF-α increase MHC I expression and the subsequent lysis of sarcomas by cytotoxic T lymphocytes (CTLs) [6]. Although previous studies have reported that high-risk HPV-positive cervical carcinoma tissues exhibit reduced MHC I expression [8,9], the exact mechanism by which HPV16E6 regulates MHC I expression and whether LT can regulate MHC I expression have not been elucidated. Here, we identify a novel molecular mechanism that LT regulated by the expression of HPV16E6 downregulates MHC I in human cervical cancer cells axis might play an important role in cancer development in cervical cancer through the suppression of immunity and cancer cell evasion from the host defense immune system.

    View all citing articles on Scopus
    View full text